Pfizer bails on Irish pension overhaul after workers union rejection

Pfizer Little Island plant Ireland
Workers at Pfizer's Little Island plant, which will make the move with Upjohn's Mylan merger, agreed to support the pension overhaul. (Pfizer)

Pfizer and some of its Irish plant workers have been locked in a yearslong battle over switching pensions from a rare no-contribution scheme to one in which employees pay toward their retirement. Nearly a year after plant unions threatened to strike over the feud, Pfizer has agreed to scuttle the overhaul.

Pfizer has ended negotiations with 700 workers at its Ringaskiddy plant to enact a direct-contribution pension plan that would require workers to pay into their retirement accounts––moving away from a so-called "direct benefit" plan that is an anomaly in private enterprise. 

Pfizer's exit followed the Ringaskiddy union's recent rejection of an Irish Workforce Relations Committee plan that would have provided for lump sum payments for retirees as well as giving employees an option to stay on their current plan with some contributions still required, according to the Irish Times. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The 200 workers at Pfizer's Little Island plant, who previously held out on the agreement, had agreed to sign on to the committee's plan, the Times reported. An additional 100 Dublin workers are on Pfizer's direct benefit plans. 

RELATED: Pfizer braces for work stoppage after announcing it will switch the pensions of Irish holdouts

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.